drugset
drugset / Trial / NCT03372850

Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations

NCT03372850 ↗

Phase 1 Unknown 96 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelBasic science

Summary

This study is a Randomized, Open-label, Multiple Dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1601 (40 mg or 20 mg) to HGP1705 (40 mg or 20 mg) After Multiple Administrations in Healthy Male Volunteers

Timeline

Start
2018-02-15
Primary completion
2018-06-15
Completion
2018-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg —
Subject Esomeprazole Small molecule 40 mg —

Indications

No indication recorded.